MBK Partners pursues Chinese pharmaceuticals firm

The private equity firm will acquire Singapore-listed Chinese drug maker, AsiaPharm, for $252 million. Shareholders respond by pushing the traded share price up to near offer level.

North Asia focused private equity firm, MBK Partners, has announced its tender offer to buy 100% of AsiaPharm Group and delist the target at an equity value of S$357.4 million $252 million. The price is a 20 times earnings multiple and around a 30% premium to AsiaPharm's recent traded prices.

MBK, which is most closely associated with partner Michael Kim who is ex-Carlyle, is making the offer in consortium with members of the management team of...

To continue reading, please login or register for free

Click for more on: mbk partners | asiapharm | delisting

Print Edition

FinanceAsia Print Edition